Eduardo Bruno Martins - Feb 6, 2025 Form 4 Insider Report for Sagimet Biosciences Inc. (SGMT)

Role
Chief Medical Officer
Signature
/s/ Elizabeth Rozek, Attorney-in-Fact
Stock symbol
SGMT
Transactions as of
Feb 6, 2025
Transactions value $
$0
Form type
4
Date filed
2/7/2025, 04:44 PM
Previous filing
Jul 23, 2024
Next filing
Jul 23, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SGMT Series A Common Stock Award $0 +34K +41.87% $0.00 115K Feb 6, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SGMT Stock Option (Right to Buy) Award $0 +138K $0.00 138K Feb 6, 2025 Series A Common Stock 138K $4.71 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. The RSUs shall vest over four equal annual installments following February 6, 2025, subject to the Reporting Person's continued service on each such vesting date.
F2 The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following February 6, 2025, subject to the Reporting Person's continued service on each such vesting date.